✦ LIBER ✦

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

✍ Scribed by José Baselga; Ian Bradbury; Holger Eidtmann; Serena Di Cosimo; Evandro de Azambuja; Claudia Aura; Henry Gómez; Phuong Dinh; Karine Fauria; Veerle Van Dooren; Gursel Aktan; Aron Goldhirsch; Tsai-Wang Chang; Zsolt Horváth; Maria Coccia-Portugal; Julien Domont; Ling-Min Tseng; Georg Kunz; Joo Hyuk Sohn; Vladimir Semiglazov; Guillermo Lerzo; Marketa Palacova; Volodymyr Probachai; Lajos Pusztai; Michael Untch; Richard D Gelber; Martine Piccart-Gebhart

Book ID: 117309599
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 320 KB
Volume: 379
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(11)61847-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lapatinib with trastuzumab for HER2-posi

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

✍ De Azambuja, Evandro (author);Holmes, Andrew P. (author);Piccart-Gebhart, Martin 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 325 KB

Lapatinib with trastuzumab for HER2-posi

✍ De Azambuja, Evandro (author);Holmes, Andrew P. (author);Piccart-Gebhart, Martin 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 325 KB

Adjuvant lapatinib for women with early-

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

✍ Paul E Goss; Ian E Smith; Joyce O'Shaughnessy; Bent Ejlertsen; Manfred Kaufmann; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 315 KB

Trastuzumab emtansine versus treatment o

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

✍ Krop, Ian E; Kim, Sung-Bae; González-Martín, Antonio; LoRusso, Patricia M; Ferre 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 422 KB

Trastuzumab emtansine versus treatment o

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

✍ Krop, Ian E; Kim, Sung-Bae; González-Martín, Antonio; LoRusso, Patricia M; Ferre 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 422 KB

## Background: Patients with progressive disease after two or more her2-directed regimens for recurrent or metastatic breast cancer have few effective therapeutic options. we aimed to compare trastuzumab emtansine, an antibody-drug conjugate comprising the cytotoxic agent dm1 linked to trastuzumab,

Efficacy and safety of neoadjuvant pertu

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

✍ Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; M 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 217 KB